Spain Pharmaceuticals and Healthcare Report Q3 2008

  • ID: 651736
  • August 2008
  • Region: Spain
  • 66 Pages
  • Business Monitor International
1 of 4


  • Almirall Prodesfarma
  • Dr Esteve
  • GlaxoSmithKline (GSK)
  • Merck & Co
  • Novartis
  • Pfizer
  • MORE

The Spain Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Spain's pharmaceuticals and healthcare industry.

Spain’s drug market was worth US$17.47bn in 2007, after showing strong growth over the past three years. However, expansion is set to slow over the forecast period, as government spending falls and cost containment policies begin to bite. Yet, even if state spending slows down, out of- pocket expenditure on both over-the-counter medicines (OTCs) and private health should play a greater role in driving market growth in future.

Biotechnology should be another area of growth. From 2000 to 2006 turnover in the biotech sector increased by 200%. Over the past few years several high-profile biotech projects have emerged, including a high-tech biomedical cluster in Barcelona and a consortium based in the capital called BioMadrid. There is also a state-led initiative, known as CIBER, the aim of which is to network a dozen biomedical research facilities. Under Spain's new National Plan for Scientific Research and Technological Innovation and Design, between 2008 and 2011 investment in R&D will rise from 1.13% to READ MORE >

Note: Product cover images may vary from those shown
2 of 4


  • Almirall Prodesfarma
  • Dr Esteve
  • GlaxoSmithKline (GSK)
  • Merck & Co
  • Novartis
  • Pfizer
  • MORE

Executive Summary 5

Spain: Pharmaceutical And Healthcare Industry SWOT 6
Spain Political SWOT 7
Spain Economic SWOT 7
Pharmaceutical Business Environment Ratings 8
Table: Western Europe Pharmaceutical Business Environment Rankings 8

Spain – Market Summary 10
Regulatory Regime 11
Intellectual Property Issues 12
Pricing And Reimbursement Issues 13
Table: Timeline – Spain's Pharmaceutical Pricing Reforms 14
Price Cut On Older Drugs 15
Reference Pricing System 15
Industry Reaction 16
Parallel Trade 17
Industry Developments 20
Foreign Sector 21
Generics Sector 22
Indigenous Manufacturing Sector 24
Research Sector Developments28
Table: Firms Active In Nanofarma Consortium 29
Government Investment 32
Industry Forecast Scenario 33
Overall Market Forecast 33
Table: Spain’s Drug Market Indicators, 2006-2012 34
Key Growth Factors – Industry 35
Table: Spain’s Health Expenditure Indicators, 2006-2012 36
Key Growth Factors – Macroeconomic 37
Table: Spain – Economic Activity 39
Patented Market Forecast 40
Table: Spain’s Patented Drugs Market Indicators, 2006- 40
OTC Market Forecast 41
Table: Spain’s OTC Market Forecast Indicators (US$mn unless otherwise stated) 41
Generics Market Forecast42
Table: Spain’s Generics And Branded Market Indicators, 2006-2012 43
Export/Import Forecast 44
Table: Pharmaceutical Trade Indicators, 2005-2012 (US$mn) 45
Medical Devices 46
Table: Spain’s Medical Device Market, 2002-2012 (US$bn unless otherwise stated) 47
Competitive Landscape 48
Manufacturers 48

Company Profiles 49
Leading Multinational Manufacturers 49
GlaxoSmithKline (GSK) 49
Pfizer 50
Novartis 52
Sanofi-Aventis 54
Merck & Co 56
Indigenous Manufacturers 57
Almirall Prodesfarma 57
Dr Esteve 60

BMI Forecast Modelling 62
How We Generate Our Pharmaceutical Industry Forecasts 62
Pharmaceutical Industry 63
Pharmaceutical Business Environment Ratings Methodology 63
Ratings Overview 63
Table: Pharmaceutical Business Environment Indicators 64
Weighting 65
Table: Weighting Of Components 65
Sources 65

Note: Product cover images may vary from those shown
3 of 4

- GlaxoSmithKline (GSK)
- Pfizer
- Novartis
- Sanofi-Aventis
- Merck & Co
- Almirall Prodesfarma
- Dr Esteve

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown


  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.


If you have a more general question about our products please try our



Our Clients

  • Pfizer Inc.
  • Grünenthal GmbH
  • GlaxoSmithKline PLC
  • Abbott Laboratories Ltd.
  • Roche Diagnostics Ltd.
  • Novo Nordisk A/S